Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1995 Jun;54(6):519–523. doi: 10.1136/ard.54.6.519

Therapeutic modulation of cytokines.

B Henderson 1
PMCID: PMC1009916  PMID: 7632100

Full text

PDF
519

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Capon D. J., Chamow S. M., Mordenti J., Marsters S. A., Gregory T., Mitsuya H., Byrn R. A., Lucas C., Wurm F. M., Groopman J. E. Designing CD4 immunoadhesins for AIDS therapy. Nature. 1989 Feb 9;337(6207):525–531. doi: 10.1038/337525a0. [DOI] [PubMed] [Google Scholar]
  2. Dougados M., Combe B., Beveridge T., Bourdeix I., Lallemand A., Amor B., Sany J. IX 207-887 in rheumatoid arthritis. A double-blind placebo-controlled study. Arthritis Rheum. 1992 Sep;35(9):999–1006. doi: 10.1002/art.1780350904. [DOI] [PubMed] [Google Scholar]
  3. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F. M., Walker J., Bijl H., Ghrayeb J. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993 Dec;36(12):1681–1690. doi: 10.1002/art.1780361206. [DOI] [PubMed] [Google Scholar]
  4. Firestein G. S., Zvaifler N. J. How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum. 1990 Jun;33(6):768–773. doi: 10.1002/art.1780330602. [DOI] [PubMed] [Google Scholar]
  5. Fry D. W., Kraker A. J., McMichael A., Ambroso L. A., Nelson J. M., Leopold W. R., Connors R. W., Bridges A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994 Aug 19;265(5175):1093–1095. doi: 10.1126/science.8066447. [DOI] [PubMed] [Google Scholar]
  6. Gearing A. J., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson A. H., Drummond A. H., Galloway W. A., Gilbert R., Gordon J. L. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature. 1994 Aug 18;370(6490):555–557. doi: 10.1038/370555a0. [DOI] [PubMed] [Google Scholar]
  7. Hannum C. H., Wilcox C. J., Arend W. P., Joslin F. G., Dripps D. J., Heimdal P. L., Armes L. G., Sommer A., Eisenberg S. P., Thompson R. C. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature. 1990 Jan 25;343(6256):336–340. doi: 10.1038/343336a0. [DOI] [PubMed] [Google Scholar]
  8. Henderson B., Blake S. Therapeutic potential of cytokine manipulation. Trends Pharmacol Sci. 1992 Apr;13(4):145–152. doi: 10.1016/0165-6147(92)90052-8. [DOI] [PubMed] [Google Scholar]
  9. Henderson B., Hardingham T., Blake S., Lewthwaite J. Experimental arthritis models in the study of the mechanisms of articular cartilage loss in rheumatoid arthritis. Agents Actions Suppl. 1993;39:15–26. doi: 10.1007/978-3-0348-7442-7_2. [DOI] [PubMed] [Google Scholar]
  10. Henderson B., Poole S. Modulation of cytokine function: therapeutic applications. Adv Pharmacol. 1994;25:53–115. doi: 10.1016/s1054-3589(08)60430-5. [DOI] [PubMed] [Google Scholar]
  11. Lewthwaite J., Blake S. M., Hardingham T. E., Warden P. J., Henderson B. The effect of recombinant human interleukin 1 receptor antagonist on the induction phase of antigen induced arthritis in the rabbit. J Rheumatol. 1994 Mar;21(3):467–472. [PubMed] [Google Scholar]
  12. Liu J. FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. Trends Pharmacol Sci. 1993 May;14(5):182–188. doi: 10.1016/0165-6147(93)90206-y. [DOI] [PubMed] [Google Scholar]
  13. Loose L. D., Sipe J. D., Kirby D. S., Kraska A. R., Weiner E. S., Shanahan W. R., Leeming M. R., Farrow P., Stack C. B., Ting N. Reduction of acute-phase proteins with tenidap sodium, a cytokine-modulating anti-rheumatic drug. Br J Rheumatol. 1993 Jun;32 (Suppl 3):19–25. doi: 10.1093/rheumatology/32.suppl_3.19. [DOI] [PubMed] [Google Scholar]
  14. McGeehan G. M., Becherer J. D., Bast R. C., Jr, Boyer C. M., Champion B., Connolly K. M., Conway J. G., Furdon P., Karp S., Kidao S. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature. 1994 Aug 18;370(6490):558–561. doi: 10.1038/370558a0. [DOI] [PubMed] [Google Scholar]
  15. Mohler K. M., Sleath P. R., Fitzner J. N., Cerretti D. P., Alderson M., Kerwar S. S., Torrance D. S., Otten-Evans C., Greenstreet T., Weerawarna K. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature. 1994 Jul 21;370(6486):218–220. doi: 10.1038/370218a0. [DOI] [PubMed] [Google Scholar]
  16. Novogrodsky A., Vanichkin A., Patya M., Gazit A., Osherov N., Levitzki A. Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors. Science. 1994 May 27;264(5163):1319–1322. doi: 10.1126/science.8191285. [DOI] [PubMed] [Google Scholar]
  17. Olds L. C., Miller J. J., 3rd C3 activation products correlate with antibodies to lipid A in pauciarticular juvenile arthritis. Arthritis Rheum. 1990 Apr;33(4):520–524. doi: 10.1002/art.1780330409. [DOI] [PubMed] [Google Scholar]
  18. Pettipher E. R., Higgs G. A., Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci U S A. 1986 Nov;83(22):8749–8753. doi: 10.1073/pnas.83.22.8749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Piguet P. F., Vesin C., Grau G. E., Thompson R. C. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine. 1993 Jan;5(1):57–61. doi: 10.1016/1043-4666(93)90024-y. [DOI] [PubMed] [Google Scholar]
  20. Rubartelli A., Sitia R. Interleukin 1 beta and thioredoxin are secreted through a novel pathway of secretion. Biochem Soc Trans. 1991 Apr;19(2):255–259. doi: 10.1042/bst0190255. [DOI] [PubMed] [Google Scholar]
  21. Saragovi H. U., Fitzpatrick D., Raktabutr A., Nakanishi H., Kahn M., Greene M. I. Design and synthesis of a mimetic from an antibody complementarity-determining region. Science. 1991 Aug 16;253(5021):792–795. doi: 10.1126/science.1876837. [DOI] [PubMed] [Google Scholar]
  22. Thorbecke G. J., Shah R., Leu C. H., Kuruvilla A. P., Hardison A. M., Palladino M. A. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7375–7379. doi: 10.1073/pnas.89.16.7375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wiesenberg I., Van der Meide P. H., Schellekens H., Alkan S. Suppression and augmentation of rat adjuvant arthritis with monoclonal anti-interferon-gamma antibody. Clin Exp Immunol. 1989 Nov;78(2):245–249. [PMC free article] [PubMed] [Google Scholar]
  24. Williams R. O., Feldmann M., Maini R. N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9784–9788. doi: 10.1073/pnas.89.20.9784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Wilson K. P., Black J. A., Thomson J. A., Kim E. E., Griffith J. P., Navia M. A., Murcko M. A., Chambers S. P., Aldape R. A., Raybuck S. A. Structure and mechanism of interleukin-1 beta converting enzyme. Nature. 1994 Jul 28;370(6487):270–275. doi: 10.1038/370270a0. [DOI] [PubMed] [Google Scholar]
  26. van de Loo F. A., Arntz O. J., Otterness I. G., van den Berg W. B. Protection against cartilage proteoglycan synthesis inhibition by antiinterleukin 1 antibodies in experimental arthritis. J Rheumatol. 1992 Mar;19(3):348–356. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES